Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)

Title:Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)

Volume: 12 Issue: 1

Author(s): Peng Zhan, Xueshun Wang, Xinyong Liu and Takayoshi Suzuki

Affiliation:

Keywords: Chelating, drug design, epigenetics, HDAC inhibitor, histone acetylation, metalloprotein, patent, synthesis.

Abstract: Background: Many laboratories have made intensive efforts to develop potent, selective, and orally bioavailable HDAC inhibitors (HDACIs). Novel HDACIs are being developed with the objective of improving potency and selectivity against specific types of cancers or non-cancer diseases.

Objective: This updated patent review is an attempt to compile the work of various researchers of HDACIs from 2012 to mid 2016, and to enlighten and surprise both newcomers in this field and devoted medicinal chemists.

Method: According to the literature research and the writers' own research experience in the discovery of HDAC inhibitors.

Results: The inhibitors possessing new chemical scaffolds have attracted immense interest because they have the ability to improve HDAC isoform specificity and pharmaceutical properties. Focus is given to emerging medicinal chemistry principles and insights into the discovery and development of HDAC inhibitors.

Conclusion: The development of effective HDACIs is shifting from trial-and-error approaches to sophisticated strategies. Effective profiling technologies will continue to have important utility.

Cite this article as:

Zhan Peng, Wang Xueshun, Liu Xinyong and Suzuki Takayoshi, Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016), Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (1) . https://dx.doi.org/10.2174/1574892811666161101102842

DOI https://dx.doi.org/10.2174/1574892811666161101102842	Print ISSN 1574-8928
Publisher Name Bentham Science Publisher	Online ISSN 2212-3970